Equillium Inc (EQ)
1.67
+0.11
(+7.05%)
USD |
NASDAQ |
May 03, 16:00
1.69
+0.02
(+1.20%)
After-Hours: 20:00
Equillium SG&A Expense (Quarterly): 3.227M for Dec. 31, 2023
SG&A Expense (Quarterly) Chart
Historical SG&A Expense (Quarterly) Data
Date | Value |
---|---|
December 31, 2023 | 3.227M |
September 30, 2023 | 3.519M |
June 30, 2023 | 3.105M |
March 31, 2023 | 3.715M |
December 31, 2022 | 5.192M |
September 30, 2022 | 4.466M |
June 30, 2022 | 4.064M |
March 31, 2022 | 3.517M |
December 31, 2021 | 2.838M |
September 30, 2021 | 2.896M |
June 30, 2021 | 2.858M |
March 31, 2021 | 2.815M |
December 31, 2020 | 2.403M |
September 30, 2020 | 2.298M |
Date | Value |
---|---|
June 30, 2020 | 2.717M |
March 31, 2020 | 2.746M |
December 31, 2019 | 2.167M |
September 30, 2019 | 2.142M |
June 30, 2019 | 2.189M |
March 31, 2019 | 2.589M |
December 31, 2018 | 1.709M |
September 30, 2018 | 1.004M |
June 30, 2018 | 0.585M |
March 31, 2018 | 0.374M |
December 31, 2017 | 0.1574M |
September 30, 2017 | 0.0338M |
June 30, 2017 | 0.1872M |
SG&A Expense Definition
SG&A expense (short for Selling, General and Administrative expense) is a line item on the income statement, though sometimes sales and marketing expenses are reported separately from general and administrative expenses.
SG&A Expense (Quarterly) Range, Past 5 Years
2.142M
Minimum
Sep 2019
5.192M
Maximum
Dec 2022
3.099M
Average
2.858M
Median
Jun 2021
SG&A Expense (Quarterly) Benchmarks
Janux Therapeutics Inc | 6.357M |
Mersana Therapeutics Inc | 10.13M |
Vera Therapeutics Inc | 6.243M |
Jasper Therapeutics Inc | 3.89M |
PepGen Inc | 4.511M |